CAL-02 is under clinical development by Eagle Pharmaceuticals and currently in Phase II for Community-Acquired Bacterial Pneumonia. According to GlobalData, Phase II drugs for Community-Acquired Bacterial Pneumonia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CAL-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CAL-02 overview

CAL-02 (combioxin) is under development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, Pseudomonas aeruginosa infections, hepatitis C infections, severe community-acquired pneumonia caused by Streptococcus pneumoniae. It is administered through intravenous route. The drug candidate comprises empty, uni-lamellar, uncoated, neutral, small liposomes composed of cholesterol and sphingomyelin and of sphingomyelin only. It acts as a decoy by mimicking microdomains targeted by diverse bacterial toxins.

It was also under development for the treatment of gram-negative bacterial infections.

Eagle Pharmaceuticals overview

Eagle Pharmaceuticals (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment of breast cancer and Vasopressin injection for blood pressure. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.

For a complete picture of CAL-02’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.